一项关于氨甲酰甲胆碱治疗放疗后口干症患者的临床试验。一项初步研究。
A clinical trial of bethanechol in patients with xerostomia after radiation therapy. A pilot study.
作者信息
Epstein J B, Burchell J L, Emerton S, Le N D, Silverman S
机构信息
Division of Oral Medicine and Clinical Dentistry, Vancouver General Hospital, British Columbia, Canada.
出版信息
Oral Surg Oral Med Oral Pathol. 1994 Jun;77(6):610-4. doi: 10.1016/0030-4220(94)90320-4.
The effects of bethanechol in the treatment of dry mouth were assessed in patients with xerostomia after radiation therapy to the head and neck. Bethanechol possesses muscarinic and nicotinic-cholinergic activity that likely accounts for its mode of action. Bethanechol (25 mg, three times daily) was not associated with significant side effects. Statistically significant increases in whole resting saliva (p = 0.003) and whole stimulated saliva (p = 0.001) were seen. In patients with pretreatment stimulated saliva volumes greater than resting saliva volumes, a positive response to subsequent use of the sialagogue was seen.
在头颈部接受放射治疗后出现口干症的患者中，评估了氨甲酰甲胆碱治疗口干的效果。氨甲酰甲胆碱具有毒蕈碱和烟碱样胆碱能活性，这可能解释了其作用方式。氨甲酰甲胆碱（25毫克，每日三次）未出现明显副作用。观察到静息全唾液量（p = 0.003）和刺激全唾液量（p = 0.001）有统计学意义的增加。在预处理时刺激唾液量大于静息唾液量的患者中，观察到随后使用催涎剂有阳性反应。
Zotero 插件